Pfizer PFE stock has been trading above its 50-day moving average since early November, indicating a potential short-term ...

Pfizer Inc's (NYSE: PFE) short interest as a percent of float has risen 8.25% since its last report. According to exchange ...

Although Pfizer (NYSE:PFE) reiterated 2025 financial guidance issued in December, the midpoints of the ranges for revenue and EPS are below consensus figures. The pharmaceutical giant is projecting ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

We recently compiled a list of the 10 Best Affordable Stocks Under $40 According to Short Sellers. In this article, we are going to take a look at where Pfizer. Inc. (NYSE:PFE) stands against the ...

As one of the world’s top pharmaceutical firms, Pfizer (PFE) is liable to see significant movement in its share price based on key fundamental data. However, once the much-anticipated event has passed ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor ...

Pfizer’s forecast for sales of its COVID-19 vaccine and treatment next year falls more than $5 billion short of the Wall Street consensus. The drugmaker’s sales tumbled in early morning trading.

Pfizer’s gene therapy candidate for Duchenne muscular dystrophy failed to meet its primary endpoint in a phase 3 trial, the company said June 12. The study tested the experimental medication, ...